0. DOCID:31719 SCORE: 0.00320996290492176
DOCNO: 16197338
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Antibodies, Monoclonal
DESCRIPTOR: Antibodies, Neoplasm
QUALIFIER: therapeutic use
QUALIFIER: drug therapy
QUALIFIER: immunology
AUTHOR: Mark C Glassy MC
AUTHOR: Michael E McKnight ME
AFFILIATION: The Rajko Medenica Research Foundation, San Diego, CA 92121, USA. markglassy@aol.com
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Expert opinion on biological therapy.
COUNTRY: England
TITLE: Requirements for human antibody cocktails for oncology.
PUBDATE: 20051001
Cancer patients receiving antibodies as monotherapy have benefited from these treatments. However, significant improvements can be made that should make the therapy more effective. Applying lessons learned from the natural oligoclonal antibody response that cancer patients mount to their own tumours suggests that cocktails of monoclonal antibodies could be formulated, which may be more effective in treating cancers. The next phase of antibody immunotherapy will include cocktails of monoclonal antibodies. Various requirements for human antibody cocktails are discussed, as well as potential limitations of this approach.

1. DOCID:31349 SCORE: 0.00320995306645334
DOCNO: 16359023
OWNER: NLM
STATUS: In-Process
AUTHOR: Toshiharu Tabata T
AUTHOR: Y Okada Y
AUTHOR: T Kondo T
AFFILIATION: Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan.
PUBTYPE: Journal Article
JOURNALTITLE: Kyobu geka. The Japanese journal of thoracic surgery.
COUNTRY: Japan
TITLE: [Lung cancer with polyarthropathy due to parvovirus B19: report of a case]
PUBDATE: 20051201
We reported a case of lung cancer with polyarthropathy induced by human parvovirus B19. A 60-year-old female with lung cancer was admitted to our hospital with polyarthropathy similar to rheumatoid arthritis. Although the abnormal accumulation of 99mTc-MDP in the bone scan film and rheumatoid factor positive were detected before operation, we diagnosed polyarthropathy induced by parvovirus B19 through the detection of parvovirus B19 IgM and B19 DNA. The joint pain gradually improved after surgical treatment for lung cancer.

2. DOCID:31618 SCORE: 0.00320987034278628
DOCNO: 16305443
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Drug Delivery Systems
QUALIFIER: administration & dosage
QUALIFIER: immunology
QUALIFIER: immunology
QUALIFIER: immunology
QUALIFIER: administration & dosage
QUALIFIER: immunology
AUTHOR: Dileep Padinjarae Vangasseri DP
AUTHOR: Su-Ji Han SJ
AUTHOR: Leaf Huang L
AFFILIATION: Center for Pharmacogenetics, School of Pharmacy, University of Pittsburgh, Pittsburgh, USA.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Current drug delivery.
COUNTRY: United Arab Emirates
TITLE: Lipid-protamine-DNA-mediated antigen delivery.
PUBDATE: 20051001
The development of novel 'new generation' vaccine systems that is based on proteins, peptides or DNA is of great current interest. However, due to the lower efficiencies of these new generation vaccines, they are seldomly used alone. Rather, their formulations often contain adjuvants, either to enhance the immune responses or to reduce dosing. The present chapter will provide a brief overview of the recent advances in peptide-based cancer vaccine adjuvants, focusing mainly on Liposome-Protamine-DNA (LPD) nanoparticle-mediated antigen delivery.

3. DOCID:30922 SCORE: 0.00288451373124616
DOCNO: 16035420
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Melanoma
DESCRIPTOR: Skin Neoplasms
PUBTYPE: Guideline
PUBTYPE: Journal Article
PUBTYPE: Practice Guideline
JOURNALTITLE: Dermatology nursing / Dermatology Nurses' Association.
COUNTRY: United States
TITLE: Melanoma: treatment guidelines for patients (part 2).
PUBDATE: 20050601
The mutual goal of the National Comprehensive Cancer Network (NCCN) and the American Cancer Society partnership is to provide patients and the generalpublic with state of the art cancer treatment information in understandable language. This treatment information is based on the professional guidelines developed by the NCCN. It is intended to assist patients in a discussion with their doctor about the treatment that is best for their specific situation. Part I of these guidelines addressed melanoma risk factors, prevention, diagnosis, stages, prevention, and clinical trials (Vol. 17, No 2, pp. 119-131). Part II describes decision trees for evaluation and treatment.

4. DOCID:29281 SCORE: 0.0024254627786307
DOCNO: 16459520
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: diagnosis
QUALIFIER: diagnosis
QUALIFIER: diagnosis
QUALIFIER: isolation & purification
AUTHOR: J J Millichap JJ
AUTHOR: A I McKendrick AI
AUTHOR: V S Drelichman VS
AFFILIATION: American University of the Caribbean School of Medicine, Sint Maarten, Netherlands Antilles. millichapj@mail.ecu.edu
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: The West Indian medical journal.
COUNTRY: Jamaica
TITLE: Streptococcus intermedius liver abscesses and colon cancer: a case report.
PUBDATE: 20051001
Certain species of bacteria are known to be associated with colorectal cancer. We report a case of adenocarcinoma of the colon with bacteraemia and liver abscesses due to Streptococcus intermedius. The isolation of this organism should prompt investigation for colorectal neoplasm, which may be present but asymptomatic, without metastases, and therefore at a curative stage.

5. DOCID:29227 SCORE: 0.0024254626014751
DOCNO: 16299785
OWNER: NLM
STATUS: In-Data-Review
AUTHOR: David S Schrump DS
AUTHOR: Dao M Nguyen DM
AFFILIATION: Thoracic Oncology Section, Surgery Branch, National Cancer Institute, Bethesda, Maryland.
PUBTYPE: Journal Article
JOURNALTITLE: Journal of surgical oncology.
COUNTRY: United States
TITLE: Novel molecular targeted therapy for esophageal cancer.
PUBDATE: 20051201
Esophageal cancers are highly lethal neoplasms which are generally refractory to conventional multidisciplinary interventions. Recent elucidation of the mechanisms of esophageal carcinogenesis, as well as preclinical studies utilizing chromatin remodeling agents and inhibitors of oncogene signaling in conjunction with conventional chemotherapeutic agents provide new opportunities for the development of potentially efficacious molecular targeted therapies for these malignancies. J. Surg. Oncol. 2005;92:257-261. (c) 2005 Wiley-Liss, Inc.

6. DOCID:29462 SCORE: 0.00242546204685278
DOCNO: 16274521
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Phytotherapy
QUALIFIER: therapeutic use
QUALIFIER: drug therapy
AUTHOR: Wigdan Al-Sukhni W
AUTHOR: Ami Grunbaum A
AUTHOR: Neil Fleshner N
AFFILIATION: Division of Urology, The Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: The Canadian journal of urology.
COUNTRY: Canada
TITLE: Remission of hormone-refractory prostate cancer attributed to Essiac.
PUBDATE: 20051001
Essiac is a popular complementary and alternative medicine (CAM) that is utilized by many cancer patients in North America. Much anecdotal reporting exists about its cancer-fighting qualities, but so far no clinical trials have been preformed to validate those claims. We describe here the case of a 64-year-old man whose hormone-refractory prostate cancer responded well to Essiac tea.

7. DOCID:29465 SCORE: 0.00242546203402888
DOCNO: 15606337
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: drug therapy
QUALIFIER: enzymology
QUALIFIER: therapeutic use
AUTHOR: Mark A Pearson MA
AUTHOR: Doriano Fabbro D
AFFILIATION: Novartis Institutes for Biomedical Research Basel, Oncology, Novartis Pharma AG, WKL.125.4.16, CH-4002, Basel, Switzerland. mark_andrew.pearson@pharma.novartis.com
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Expert review of anticancer therapy.
COUNTRY: England
TITLE: Targeting protein kinases in cancer therapy: a success?
PUBDATE: 20041201
The fundamental role of kinases in cancer progression has promoted the development of a plethora of therapeutic inhibitors. Despite the promise of effective treatment with little associated toxicity, the clinical experience with these agents has been mixed. This review will summarize recent advances made in the development of kinase inhibitors to highlight emerging issues and the strategies by which they being addressed.

8. DOCID:29425 SCORE: 0.00222062626724961
DOCNO: 15387660
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: isolation & purification
QUALIFIER: chemistry
QUALIFIER: isolation & purification
QUALIFIER: isolation & purification
AUTHOR: Leonard A McDonald LA
AUTHOR: Laurel R Barbieri LR
AUTHOR: Valerie S Bernan VS
AUTHOR: Jeffrey Janso J
AUTHOR: Peter Lassota P
AUTHOR: Guy T Carter GT
AFFILIATION: Wyeth-Research, 401 North Middletown Road, Pearl River, New York 10965, USA. mcdonal@wyeth.com
PUBTYPE: Journal Article
JOURNALTITLE: Journal of natural products.
COUNTRY: United States
TITLE: 07H239-A, a new cytotoxic eremophilane sesquiterpene from the marine-derived Xylariaceous fungus LL-07H239.
PUBDATE: 20040901
07H239-A (1), a new eremophilane sesquiterpene from a marine-derived xylariaceous fungus, was isolated, characterized, and shown to be cytotoxic toward a variety of cancer cell lines, with some selectivity for a CCRFCEM leukemia line (IC(50) = 0.9 microg/mL).

9. DOCID:31761 SCORE: 0.00221680448193251
DOCNO: 15734683
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: physiology
QUALIFIER: physiology
QUALIFIER: physiology
QUALIFIER: physiology
QUALIFIER: physiology
AUTHOR: Judith Campisi J
AFFILIATION: Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA. jcampisi@lbl.gov
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Cell.
COUNTRY: United States
TITLE: Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors.
PUBDATE: 20050201
Cells from organisms with renewable tissues can permanently withdraw from the cell cycle in response to diverse stress, including dysfunctional telomeres, DNA damage, strong mitogenic signals, and disrupted chromatin. This response, termed cellular senescence, is controlled by the p53 and RB tumor suppressor proteins and constitutes a potent anticancer mechanism. Nonetheless, senescent cells acquire phenotypic changes that may contribute to aging and certain age-related diseases, including late-life cancer. Thus, the senescence response may be antagonistically pleiotropic, promoting early-life survival by curtailing the development of cancer but eventually limiting longevity as dysfunctional senescent cells accumulate.

10. DOCID:31974 SCORE: 0.00204142925530474
DOCNO: 16399449
OWNER: NLM
STATUS: In-Process
QUALIFIER: drug therapy
QUALIFIER: radiotherapy
AUTHOR: Bernard J Cummings BJ
AFFILIATION: Department of Radiation Oncology, Princess Margaret Hospital/University of Toronto, Toronto, Ontario M5G 2M9, Canada. Bernard.Cummings@rmp.uhn.on.ca
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Seminars in oncology.
COUNTRY: United States
TITLE: Current management of anal canal cancer.
PUBDATE: 20051201
Combined-modality therapy consisting of radiation therapy and 5-fluorouracil plus mitomycin remains the standard treatment for localized anal canal cancer, permitting preservation of organ function and achieving high response and survival rates. Current trials are evaluating the ability to deliver higher doses of radiation therapy over shorter intervals. Currently, the most common indication for radical surgery is failure of chemoradiation. Metastatic disease is less responsive to chemoradiation treatment. Neoadjuvant and adjuvant strategies are being evaluated, and additional drugs including capecitabine, irinotecan, and oxaliplatin are being assessed in treatment of localized and advanced disease.

11. DOCID:31970 SCORE: 0.00204142917605032
DOCNO: 15315810
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: virology
QUALIFIER: virology
AUTHOR: Simon J Talbot SJ
AUTHOR: Dorothy H Crawford DH
AFFILIATION: Centre for Infectious Diseases, University of Edinburgh, R(D)SVS, Summerhall, Edinburgh EH9 1QH, UK. stalbot@ed.ac.uk
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: European journal of cancer (Oxford, England : 1990)
COUNTRY: England
TITLE: Viruses and tumours--an update.
PUBDATE: 20040901
In the 40 years since the publication of the article by Harris (Eur J Cancer 1965, 1, 183-188), considerable progress has been made towards the understanding of the contribution of infectious agents to the development of tumours. It is estimated that 15-20% of human malignancies may have an infectious aetiology. This article attempts to summarise the current level of our knowledge with respect to tumour-associated viruses, and to place this in the context of the earlier article by Harris (Eur J Cancer 1965, 1, 183-188).

12. DOCID:31490 SCORE: 0.0020414221836266
DOCNO: 15993607
OWNER: NLM
STATUS: In-Process
AUTHOR: Shugeng Cao S
AUTHOR: Caleb Foster C
AUTHOR: John S Lazo JS
AUTHOR: David G I Kingston DG
AFFILIATION: Department of Chemistry, M/C 0212, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061, USA.
PUBTYPE: Journal Article
JOURNALTITLE: Bioorganic & medicinal chemistry.
COUNTRY: England
TITLE: Four diterpenoid inhibitors of Cdc25B phosphatase from a marine anemone.
PUBDATE: 20051001
Three new diterpenoids and one known diterpenoid have been isolated from a sea anemone of the order Actiniara, and the structures of the new compounds, actiniarins A-C (1-3) were established on the basis of extensive 1D and 2D NMR spectroscopic data interpretation. Compound 1 has a six-membered ring hemiacetal ring, and the equilibrium of this ring is discussed. All the isolates were evaluated for their inhibition of Cdc25B and for cytotoxicity against the A2780 ovarian cancer cell line.

13. DOCID:29140 SCORE: 0.00194422294100768
DOCNO: 14706331
AUTHOR: Inese Smukste I
AUTHOR: Brent R Stockwell BR
AFFILIATION: Whitehead Institute for Biomedical Research, Nine Cambridge Center, Cambridge, MA 02142, USA.
PUBTYPE: Comment
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Cancer cell.
COUNTRY: United States
TITLE: Restoring functions of tumor suppressors with small molecules.
PUBDATE: 20031201
Developing small molecule inhibitors of oncoproteins, which are activated in tumor cells, is a newly popular strategy for cancer-related drug discovery. The complementary strategy, developing small molecules that restore the function of missing tumor suppressors, is much more difficult to realize. However, in this issue of Cancer Cell, Kau et al. report the discovery of small molecules that reverse some cellular consequences of the loss of the tumor suppressor PTEN.

14. DOCID:31710 SCORE: 0.00193662860578669
DOCNO: 11880180
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: prevention & control
QUALIFIER: prevention & control
QUALIFIER: therapeutic use
AUTHOR: Natalia V Popova NV
AFFILIATION: Dermatology Department, Columbia University, 630W 168 Street VC 15, New York, NY 10032, USA. nvp2002@columbia.edu
PUBTYPE: Journal Article
JOURNALTITLE: Cancer letters.
COUNTRY: Ireland
TITLE: Perinatal selenium exposure decreases spontaneous liver tumorogenesis in CBA mice.
PUBDATE: 20020501
This study was designed to investigate the influence of neonatal selenium (an anticarcinogenic agent) exposure on spontaneous liver tumor formation in adult mice. Pregnant CBA mice were administered selenium during the last week of pregnancy and for ten days following parturition. Selenium significantly reduced the incidence of spontaneous hepatomas in adult male progeny, while having no effect on the lower hepatoma incidence in adult females. The data indicate that neonatal selenium alters hepatoma incidence in a sex-dependent manner. This study represents the model of neonatal cancer prevention.